DefinitionThis section has been translated automatically.
Stage I of rosacea with temporary, seizure-like flushing of the face caused by numerous stimuli.
Occurrence/EpidemiologyThis section has been translated automatically.
You might also be interested in
EtiopathogenesisThis section has been translated automatically.
- Not fully clarified.
- Genetic dispositions with abnormalities in innate immunity (these concern the antimicrobial peptide cathelicidin and its activator kallikrein 5), accompanying vascular dysfunction is considered the most likely cause. From this, a vicious circle is recruited from dermal damage, vasodilatation, vascular damage and inflammatory tissue reaction.
- Trigger factors are UV rays, X-rays, heat, cold, excitation, coffee, alcohol, tea, hot spices (pepper, curry), temperature fluctuations, external (too fatty) cosmetics and hormonal fluctuations (menstruation, pregnancy, menopause). The influence of Helicobacter pylori is controversially discussed.
ManifestationThis section has been translated automatically.
LocalizationThis section has been translated automatically.
face, cheeks, nose, forehead, chin, lateral neck areas
Clinical featuresThis section has been translated automatically.
Precursory form (transient erythema): First signs of incipient rosacea with a tendency to flush-like, functional erythema, which manifests itself as fleeting, soft red or even bright red spots on the face. They disappear completely in the early stages of rosacea. They reappear with stimuli such as: change from cold to warmth, spicy food, hot drinks like tea or coffee, alcohol, stress situations. These flush symptoms are accompanied by heat waves, sometimes with an increased tendency to sweat, which is perceived as uncomfortable by those affected.
Over the course of months or years, the redness persists for hours and days, later permanently. Patients also complain about the seizure-like and variable blood fillings of the affected regions. The affected skin becomes increasingly firm due to a persistent slushy oedema (+ slight dermal fibrosis) (a flat erythema develops into red plaque). There is a tendency towards the development of telangiectasias (rosacea teleangiectatica), which are mainly nasolabial and localized in the cheek area.
Fig. see below Rosacea
TherapyThis section has been translated automatically.
External therapyThis section has been translated automatically.
Brimonidine (preparation Mirvaso®) can be recommended for the treatment of erythematous rosacea. In clinical trials, brimonidine gel has shown significantly greater improvements in facial flushing in rosacea than placebo. Brimovudine is a very effective therapy for rosacea facial erythema. The preparation works by reversible (!) vasoconstriction over a period of 12 hours. The onset of action is often detectable after only 30 minutes. Experience shows that the success of treatment improves with increasing treatment duration. The most frequent side effects (incidence ≥ 1%) during short-term treatment were flushing, erythema, burning of the skin and contact dermatitis.
The most common side effects during long-term use (incidence: ≥4%) were: flushing (10%), redness (8%), worsening rosacea (5%), nasopharyngitis (5%), burning of the skin (4%), increased intraocular pressure (4%) and headache (4%).
The gel is applied daily in approximately pea-size amounts to the affected areas. The effect is expected within 30 minutes.
Radiation therapyThis section has been translated automatically.
Diet/life habitsThis section has been translated automatically.
Note(s)This section has been translated automatically.
The maximum variant of erythematous rosacea is called rosacea edematosa or M. Morbihan.
LiteratureThis section has been translated automatically.
- Del Rosso JQ et al (2013) Management of facial erythema of rosacea: what is the role of topical α-adrenergic receptor agonist therapy J Am Acad Dermatol 69 (Suppl 1): S44-56
- Lim HS et al (2014) The efficacy of intense pulsed light for treating erythematotelangiectatic rosacea is related to severity and age. Ann Dermatol 26:491-495
- Piwnica D et al (2014) Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine. J Dermatol Sci 75:49-54
- Urban J et al (2014) Optical coherence tomography imaging of erythematotelangiectatic rosacea during treatment with brimonidine topical gel 0.33%: a potential method for treatment outcome assessment. J Drugs Dermatol 13:821-826
Outgoing links (9)Brimonidine; Cathelicidins; Immunity, innate; Kallikrein; Laser; Prevalence; Rosacea; Solid facial edema in rosacea; Teleangiectasia;
Please ask your physician for a reliable diagnosis. This website is only meant as a reference.